Brian Skorney
Stock Analyst at Baird
(3.54)
# 904
Out of 4,980 analysts
115
Total ratings
46.34%
Success rate
7.48%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $14.01 | +271.16% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $17.22 | +103.25% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $60.02 | +101.62% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $13.28 | +140.96% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $142.61 | +78.81% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $555.83 | +5.61% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $74.93 | -26.60% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $115.25 | -13.23% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.35 | +124.72% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.44 | +1,024.86% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $8.41 | +137.81% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.30 | +481.40% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.56 | +180.90% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $278.51 | -22.80% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $141.25 | +27.43% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.20 | +438.46% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $35.00 | +77.14% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.57 | +307.52% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $37.11 | +69.77% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $388.55 | -16.36% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $16.20 | -38.27% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $3.57 | +7,463.03% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.16 | +44.23% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.79 | +16,659.78% | 3 | May 7, 2018 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $14.01
Upside: +271.16%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $17.22
Upside: +103.25%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $60.02
Upside: +101.62%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $13.28
Upside: +140.96%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $142.61
Upside: +78.81%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $555.83
Upside: +5.61%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $74.93
Upside: -26.60%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $115.25
Upside: -13.23%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.35
Upside: +124.72%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.44
Upside: +1,024.86%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $8.41
Upside: +137.81%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.30
Upside: +481.40%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.56
Upside: +180.90%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $278.51
Upside: -22.80%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $141.25
Upside: +27.43%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.20
Upside: +438.46%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $35.00
Upside: +77.14%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.57
Upside: +307.52%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $37.11
Upside: +69.77%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $388.55
Upside: -16.36%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $16.20
Upside: -38.27%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $3.57
Upside: +7,463.03%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.16
Upside: +44.23%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.79
Upside: +16,659.78%